Biora Therapeutics, Inc. (BIORQ) - Total Liabilities
Based on the latest financial reports, Biora Therapeutics, Inc. (BIORQ) has total liabilities worth $121.13 Million USD as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Biora Therapeutics, Inc. to see how much of total assets are deployed in long-term investments.
Biora Therapeutics, Inc. - Total Liabilities Trend (2018–2023)
This chart illustrates how Biora Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Biora Therapeutics, Inc. (BIORQ) total assets.
Biora Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Biora Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lake Winn Resources Corp
V:LWR
|
Canada | CA$1.89 Million |
|
Rimo International Lestari Tbk PT
JK:RIMO
|
Indonesia | Rp569.64 Billion |
|
WELLFIELD TECHNOLOG. INC.
F:K8D
|
Germany | €35.06 Million |
|
Biora Therapeutics Inc
NASDAQ:BIOR
|
USA | $121.13 Million |
|
Venture Life Group PLC
LSE:VLG
|
UK | GBX17.76 Million |
|
Prostatype Genomics AB
ST:PROGEN
|
Sweden | Skr7.36 Million |
|
Wingara AG Ltd
AU:WNR
|
Australia | AU$1.31 Million |
|
Aranjin Resources Ltd
V:ARJN
|
Canada | CA$1.30 Million |
Liability Composition Analysis (2018–2023)
This chart breaks down Biora Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Biora Therapeutics, Inc. balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 8.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biora Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biora Therapeutics, Inc. (2018–2023)
The table below shows the annual total liabilities of Biora Therapeutics, Inc. from 2018 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $132.64 Million | -14.87% |
| 2022-12-31 | $155.81 Million | -19.61% |
| 2021-12-31 | $193.81 Million | -25.86% |
| 2020-12-31 | $261.43 Million | +40.86% |
| 2019-12-31 | $185.60 Million | +21.02% |
| 2018-12-31 | $153.37 Million | -- |
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-fre… Read more